目的探讨术前新辅助内分泌治疗在老年乳腺癌治疗中的意义。
Objective To study the curative effect of preoperative endocrine therapy on breast cancer in elderly women.
这项研究结果也显示,相比较新辅助化疗,罕见对新辅助内分泌治疗有完全的缓解。
The results also indicate that a complete response to neoadjuvant endocrine therapy is rare compared to neoadjuvant chemotherapy.
结论术前新辅助内分泌治疗在高龄乳腺癌患者中能达到原发病灶和区域淋巴结降期的目的。
Conclusion Preoperative endocrine therapy for breast cancer of elderly women could effectively delay or remit the advancement of the tumor.
术前辅以新辅助化疗,术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
选择性COX - 2抑制剂可联合化疗、内分泌治疗及生物治疗等,作为肿瘤治疗的辅助药物应用于临床,为乳腺癌的治疗提供一种新的途径。
Selective COX-2 inhibitors can combine with chemotherapy, endocrine therapy and biotherapy. It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.
结果:36例患者中29例(80%)经新辅助治疗后病情缓解,可以手术。其中27例由化疗获得,2例由内分泌治疗获得。
Results: After neoadjuvant therapy, 29 (80%) patients got partial response and some of the primary inoperable lesions became respectable, 27cases by chemotherapy, 2cases by endocrine therapy.
结果:36例患者中29例(80%)经新辅助治疗后病情缓解,可以手术。其中27例由化疗获得,2例由内分泌治疗获得。
Results: After neoadjuvant therapy, 29 (80%) patients got partial response and some of the primary inoperable lesions became respectable, 27cases by chemotherapy, 2cases by endocrine therapy.
应用推荐